The Masco Group, headquartered in Milan, Italy, acquired a majority stake in KeyPlants, a deal Masco officials say will strengthen its leadership in engineering technologies for life sciences.

KeyPlants provides standardized as well as customized process-integrated modular prefabricated facility solutions. The company reports that it has a fully integrated supply chain with more than 45 years of experience in project engineering, production, and delivery, and has supplied more than 3,500 high-specification modules to at least 30 countries.

The partnership is expected to strengthen Masco Group by combining its expertise in clean utilities and process technologies with KeyPlants’ experience in prefabricated, modular facility solutions, according to Luca Borella, CEO of the Masco Group. It will support stronger value propositions for global supply chain challenges such as flexibility, reliability and fast-track manufacturing timelines to a global customer base of biopharmaceutical manufacturers and CDMOs focused on biologics, pharma, and advanced therapy medicinal products (ATMPs), such as cell and gene therapies, he adds.

KeyPlant officials say the company delivers turnkey facilities, including process equipment, utilities, and digital solutions.

“KeyPlants’ management and team are fully committed to this partnership with Masco Group,” says Jörgen Harrysson, managing director and board member of KeyPlants. “Its global presence and network enables KeyPlants to continue with our strategy to serve existing and new clients with our fast-track solutions, including customized facilities as well as standardized PODs. We are also thrilled to be able to expand our presence and offerings in North America, Europe, and Africa.”

“Masco Group is part of RSBG SE, a German-based long-term industrial partner of successful medium-sized companies, pursuing a buy-and-build strategy and focusing on competences and areas which are of great importance during global transformations.” comments Frans K. A. Maas, board member of the Masco Group. Board Member. “This acquisition supports the vision to become a technology-leading turnkey provider, in particular in the growing and demanding markets of biologics, vaccines, and advanced therapy medicinal products.”

Previous articleSmoother Waters: Turnaround Pays Dividends in Q3
Next articleQualitative, Semi-quantitative, and Quantitative Immunodiagnostics for COVID-19